Gilead Sciences GILD Other — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gilead Sciences's other — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gilead Sciences's other — total revenues?
- Gilead Sciences (GILD) reported other — total revenues of $58M in Q1 2026.
- How has Gilead Sciences's other — total revenues changed year-over-year?
- Gilead Sciences's other — total revenues decreased by 17.1% year-over-year, from $70M to $58M.
- What is the long-term trend for Gilead Sciences's other — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's other — total revenues has grown at a 0.8% compound annual growth rate (CAGR), from $281M to $290M.
- What does other — total revenues mean?
- The total sales revenue generated by the company's secondary or non-core product lines.
- How do you interpret other — total revenues?
- An increase suggests successful monetization of secondary assets or stable demand for legacy products, while a decrease may indicate product sunsetting or a strategic shift away from these non-core areas.
- How does other — total revenues compare across companies?
- Peers often report this as 'Other Products' or 'Non-Core Revenue,' and it typically represents a small, declining portion of total revenue as companies focus on high-growth therapeutic areas.